Risedronate Sodium Drug Asset Due Diligence Report 2026

This Risedronate Sodium Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

136

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Risedronate Sodium can convert its Small molecule drug profile and FDPS biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Risedronate Sodium (query alias: risedronate)
Modality / target	Small molecule drug; FDPS; FDPS inhibitors
Highest global status	Approved
Originator	Procter & Gamble Pharmaceuticals, Inc.
Active developers	Allergan Pharmaceuticals International Ltd., AbbVie, Inc., Changzhou Huasheng Pharmaceutical Co. Ltd.

The MCP disease footprint includes Osteoporosis, Glucocorticoid-induced osteoporosis, Osteitis Deformans. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07471815	Phase 2	Active, not recruiting	30	ORR
ChiCTR2600120465	Not Applicable	Pending	30	Objective Response Rate
CTR20253916	Not Applicable	已完成	12	Not disclosed

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

The Impact of Prophylactic Bisphosphonates on Radiation-Induced Rib Fractures and Chest Wall Pain in Peripheral Lung Tumor SBRT: A Randomized, Double-Blind, Placebo-Controlled Study

Not Applicable; n=not disclosed; evaluation: not stated. Reported fields: -; Chest wall V30 = 20 cc ( 0.5 - 314)

EFFECTS OF LONGTERM ORAL BISPHOSPHONATE THERAPY IN PATIENTS WITH OSTEOPOROSIS: WHAT DO WE DO NEXT?

Not Applicable; n=57; evaluation: not stated. Reported fields: AE = There were no cases of significant adverse effects specifically atypical femur fractures or osteonecrosis of jaw

A Randomized Clinical Trial of Prophylactic Risedronate for Patients With Peripheral Lung Tumors Treated With SBRT

Phase 2; n=84; evaluation: not stated. Reported fields: Changes in Mean Cortical Thickness(Mean) = 7.14 percent change in mm cortical thickne (Standard Error, 2.93); -; Changes in Mean Cortical Thickness(Mean) = 4.24 percent change in mm cortical thickne (Standard Error, 3.04)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Risedronate Sodium addresses Osteoporosis, Glucocorticoid-induced osteoporosis, Osteitis Deformans. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2018-06-25	Alvogen announces distribution agreement with Theramex in CEE, Russia and CIS countries	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Risedronate sodium inclusion compound, preparation and application”. The milestone feed surfaced a patent-application signal described as “Adjuvant containing zinc aluminum risedronate, and application thereof”. The milestone feed surfaced a patent-application signal described as “Preparation of zinc risedronate micro/nano adjuvant and use thereof as vaccine adjuvant”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO